<DOC>
	<DOCNO>NCT00828165</DOCNO>
	<brief_summary>This Phase 1 study , involve 1-day dosing period ( 3 dose period per subject ) , design test safety investigational study drug ARRY-300 healthy subject . Approximately 12 healthy subject US enrol study .</brief_summary>
	<brief_title>A Safety Study ARRY-300 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Key Healthy male female ( female must nonchildbearing potential ) age 18 50 year , inclusive . Body mass index ( BMI ) 18 kg/m2 35 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) &lt; 113 kg ( 280 lb ) . Additional criterion exist . Key Evidence history clinically significant hematologic , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , dermatologic , allergic disease ( include drug allergy clinically significant remote , exclude untreated , asymptomatic , seasonal allergy time dose ) . A condition possibly affect drug absorption ( e.g. , gastrectomy ) . Women pregnant breastfeeding . A positive test drug alcohol . Use tobacco nicotinecontaining product excess 5 cigarette per day , daily use pipe , cigar , chew tobacco nicotine gum patch . Treatment investigational drug within 30 day prior first dose study drug . Use prescription nonprescription drug , vitamin , grapefruit juice , dietary herbal supplement within 14 day prior first dose study drug . As exception , acetaminophen may use dos ≤ 1 g/day ibuprofen may use dos ≤ 800 mg/day 24 hour prior first dose study drug . Blood donation ≥ 1 pint within 30 day prior first dose study drug . Evidence hepatitis B C , human immunodeficiency virus ( HIV ) infection upon serological testing . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>